Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC. We’re routinely using next-generation sequencing [NGS] in ...

New Working Group to Evaluate Clinical Utility of NGS-Based Testing to Inform Coverage After many years of steady development in DNA sequencing, the scientific community is reaching an exciting ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

Two abstracts involving real-world data (RWD) presented at the 2021 American Society of Clinical Oncology Quality Care Symposium tracked the uptake of next-generation sequencing (NGS) and biomarker ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Clinical utility of next-generation sequencing (NGS)-based genomic profiling of advanced solid tumors in routine clinical practice. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving ...

Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...

Recommendations on the use of next-generation sequencing (NGS) tests for patients with metastatic cancer have been issued by the European Society for Medical Oncology (ESMO), the first recommendations ...

GMP-qualified NGS adventitious virus detection with a predictable 28-day turnaround and U.S.-based end-to-end support PHILADELPHIA, March 4, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...